

Referenzen:

1. Shanafelt TD et al. Update From the E1912 Trial Comparing Ibrutinib & to FCR in Patients with Untreated Chronic Leukemia (CLL). ASH 2019; Oral Presentation #33.
2. Woyach JA, et al.: Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. *N Engl J Med* 2018;379(26):2517–28.
3. Moreno C et al. Ibrutinib Plus Obinutuzumab Versus Chlorambucil Plus Obinutuzumab in First-Line Treatment of Chronic Lymphocytic Leukaemia (iLLUMINATE): A Multicentre, Randomised, Open-Label, Phase 3 Trial. *Lancet Oncol* 2019; 20(1):43–56.